ArticleBritish journal of cancer2000
Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption.
Article in British journal of cancer, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 117 citations in OpenAlex.
- Cutting to the core: Proteases in the tumor-bone interface and metastatic progression.Biochimica et biophysica acta. Reviews on cancer · 2026Review
- Article
- Prostate cancer bone metastases biology and clinical management (Review).Oncology letters · 2023Review
- The role of prostate-specific antigen in the osteoblastic bone metastasis of prostate cancer: a literature review.Frontiers in oncology · 2023Review
- Investigating the specificity of endothelin-traps as a potential therapeutic tool for endothelin-1 related disorders.World journal of diabetes · 2022Article
- Reciprocal interactions between osteoclasts and nociceptive sensory neurons in bone cancer pain.Pain reports · 2021Review
- Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.Journal of bone oncology · 2019Review
- Mesenchymal Stromal Cells: Emerging Roles in Bone Metastasis.International journal of molecular sciences · 2018Review
- New therapeutic targets for cancer bone metastasis.Trends in pharmacological sciences · 2015Review
- Cancer-targeted therapies and radiopharmaceuticals.BoneKEy reports · 2015Review
- Big endothelin changes the cellular miRNA environment in TMOb osteoblasts and increases mineralization.Connective tissue research · 2014Article
- Prostate cancer and bone: the elective affinities.BioMed research international · 2014Review
- The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.Frontiers in oncology · 2014Review
- Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.The Prostate · 2013Article
- Interaction among cells of bone, immune system, and solid tumors leads to bone metastases.Clinical & developmental immunology · 2013Review
- Permissive role of endothelin receptors in tumor metastasis.Life sciences · 2012Review
- The PCa Tumor Microenvironment.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2011Article
- Novel therapies for metastatic castrate-resistant prostate cancer.Journal of the National Cancer Institute · 2011Review
- Steps in prostate cancer progression that lead to bone metastasis.International journal of cancer · 2011Review
- Probing the invasiveness of prostate cancer cells in a 3D microfabricated landscape.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The causes for the propensity of metastasized prostate cancer cells to grow in bone and to induce osteoblastic lesions remain unresolved. Co-culture of human prostate cancer cell lines with bone slices was determined to increase the level of endothelin-1 (ET-1) mRNA and its production. ET-1 is an ejaculate protein that also stimulates osteoblasts. Osteoclastic bone resorption was significantly blocked by the presence of androgen-independent prostate cancer cells in a dose-dependent manner as that of synthetic ET-1. The inhibition could be neutralized by specific ET-1 antibody, indicating the association of prostate cancer-derived ET-1 with inhibition of bone resorption. The combined ET-1 activity on osteoclasts and osteoblasts disrupts bone remodelling. ET-1 production is also elevated in the presence of prostate-specific antigen (PSA). ET-1 in turn enhances DNA synthesis of prostate cancer cells. Interactions among cancer cells, bone, ET-1 and PSA may be critical in cancer growth and lesions in bone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.